SecBot SecBot
SECBOTREPLAY Home › Report › RCUS

RCUS · Arcus Biosciences reported Q4 and full-year 2025 financial results,…

Arcus Biosciences, Inc. · 8-K filed Feb 25, 2026 at 16:08 ET

At the news

MIXEDIMPACT 6/10

8-K filed Feb 25, 2026 at 16:08 ET

Arcus Biosciences reported Q4 and full-year 2025 financial results, highlighting strong clinical data for its drug candidate casdatifan in kidney cancer, including a median progression-free survival of 15.1 months and a 45% response rate. The company maintains a robust $1 billion cash position with runway into 2028, while R&D expenses increased to $121 million in Q4. Revenue declined slightly to $33 million from $36 million year-over-year.

  • Updated data for casdatifan showed 15.1 months median PFS and 45.2% confirmed response rate in 100mg cohort
  • Cash, cash equivalents and marketable securities were $1.0 billion as of December 31, 2025
  • Q4 2025 revenue was $33 million, down from $36 million in Q4 2024
  • Q4 2025 R&D expenses were $121 million, up from $111 million in Q4 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access